Trial Profile

A Phase 1/2 Multicenter, Open-label, Dose-escalation Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies (CASSANDRA)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 09 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IDP 121 IDP Pharma (Primary)
Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Multiple myeloma
Focus Adverse reactions; Therapeutic Use
Acronyms CASSANDRA
Sponsors IDP Pharma

Most Recent Events

01 May 2025 Planned End Date changed from 22 Dec 2025 to 22 Mar 2026.
01 May 2025 Planned primary completion date changed from 22 May 2024 to 22 Dec 2025.
26 Oct 2023 According to IDP Pharma media release, first patient has been successfully dosed in Phase I/II dose escalation and expansion study in relapsed/refractory hematological malignancies.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com